Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children; Notice of Meeting, 13198-13199 [05-5377]
Download as PDF
13198
Federal Register / Vol. 70, No. 52 / Friday, March 18, 2005 / Notices
sprawl provides new roosts for bats in
homes and buildings while reducing
available natural roosts and putting
humans in more frequent contact with
bats. The largest public health concern
with respect to bat exposure is the
transmission of rabies virus—about 75%
of human rabies deaths are from batassociated rabies variants. The current
U.S. guidelines for animal rabies
prevention and control recommend that
bats be excluded from houses and
adjacent structures to prevent direct
association with humans. While direct
association with bats is certainly a risk
factor for rabies transmission, little is
known about the effects of indirect
association with bats and potential
adverse health effects. This is of public
health concern because many
organizations actually promote
interactions between bats and humans,
without consideration of public health
consequences.
The questionnaire will establish bat
exposure history, general personal
health history including frequency of
post-exposure prophylaxis for rabies
and knowledge and attitudes pertaining
to bat roosts. The Colorado State
University/United States Geological
Survey (USGS) study provides both a
background for bat and rabies virus
ecology in the Fort Collins area, and the
ability of conservation and health issues
to be relayed to the public.
We will evaluate health outcomes
among household members by
administering a survey focused on
frequency and nature of hospital/clinic
visits, frequency of bat exposure, and
frequency of post-exposure prophylaxis
(PEP) for rabies.
The list of households with roosts is
provided by Colorado State University
bat researchers, identified through
radio-tagging of bats. We plan to
improve the knowledge of the ecology of
bats and associated rabies transmission
by assimilating rabies prevalence data in
a bat population with data regarding the
roost ecology and bat/human interaction
ecology in a rapidly sprawling suburban
area, Ft. Collins, Colorado. There is no
cost to the respondents other than their
time. The total annualized burden hours
are 178.
ANNUALIZED BURDEN TABLE
Number of
respondents
Respondents
Households with Bats (n=45) ......................................................................................................
Households without Bats (n=153) ...............................................................................................
Dated: March 14, 2005.
Betsey Dunaway,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 05–5384 Filed 3–17–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
General Notice.
Health Resources and Services
Administration, HHS.
ACTION: General notice.
AGENCY:
Background
This notice supplements the summer
2004 HRSA Preview which announced
the availability of fiscal year (FY) 2005
funding for new and competing
continuation applications for Healthy
Start. Healthy Start, authorized under
section 330H of the Public Health
Service Act, strengthens communities to
effectively address the causes of infant
mortality, low birth weight and other
poor perinatal outcomes for women and
infants. Recently, new guidance became
available with regards to funding FY
2005 Healthy Start programs.
SUMMARY: Following the Senate
Committee’s recommendation, the
Health Resources and Services
Administration (HRSA) will give
VerDate jul<14>2003
16:14 Mar 17, 2005
Jkt 205001
funding preference during the FY 2005
competition to current and former
Healthy Start grantees, including those
whose Healthy Start grant application
was approved but not funded in FY
2004.
Senate Report 108–345 at 54 (2004)
accompanying the Consolidated
Appropriations Act, 2005 (Pub. L. 108–
447) states ‘‘The Committee urges HRSA
to give preference to current and former
grantees with expiring or recently
expired project periods. This should
include grantees whose grant
applications were approved but not
funded during fiscal year 2004.’’
FOR FURTHER INFORMATION CONTACT:
Maribeth Badura, Director, Division of
Healthy Start and Perinatal Services,
Maternal and Child Health Bureau,
HRSA, Room 18–20, Parklawn Building,
5600 Fishers Lane, Rockville, Maryland
20857; telephone (301) 443–0543; e-mail
MBadura@hrsa.gov.
Dated: March 14, 2005.
Elizabeth M. Duke,
Administrator.
[FR Doc. 05–5378 Filed 3–17–05; 8:45 am]
BILLING CODE 4165–15–P
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
81
275
Number of responses/respondent
Average burden/response
(in hours)
1
1
30/60
30/60
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Committee on Heritable
Disorders and Genetic Diseases in
Newborns and Children; Notice of
Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Public Law 92–463), notice is hereby
given of the following meeting:
Name: Advisory Committee on Heritable
Disorders and Genetic Diseases in Newborns
and Children (ACHDGDNC).
Dates and Times: April 21, 2005, 9 a.m. to
5 p.m., April 22, 2005, 9 a.m. to 5 p.m.
Place: Ronald Reagan Building and
International Trade Center, 1300
Pennsylvania Avenue, NW., Washington, DC
20004.
Status: The meeting will be open to the
public with attendance limited to space
availability.
Purpose: The Advisory Committee
provides advice and recommendations
concerning the grants and projects authorized
under the Heritable Disorders Program and
technical information to develop policies and
priorities for this program that will enhance
the ability of the State and local health
agencies to provide for newborn and child
screening, counseling and health care
services for newborns and children having or
at risk for heritable disorders. Specifically,
the Advisory Committee shall advise and
guide the Secretary regarding the most
appropriate application of universal newborn
screening tests, technologies, policies,
E:\FR\FM\18MRN1.SGM
18MRN1
Federal Register / Vol. 70, No. 52 / Friday, March 18, 2005 / Notices
guidelines and programs for effectively
reducing morbidity and mortality in
newborns and children having or at risk for
heritable disorders.
Agenda: Presentations will include a
discussion of the report from the American
College of Medical Genetics; reports from the
Laboratory Standards and Procedures;
Education and Training; and Follow-Up
Subcommittees; a discussion on the
educations process for parents and an
assessment system and guidelines for state
newborn screening follow-up.
Proposed agenda items are subject to
change as priorities indicate.
Public Comments: Time will be provided
each day for public comment. Individuals
who wish to provide public comment or who
plan to attend the meeting and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
ACHDGDNC Executive Secretary, Michele A.
Lloyd-Puryear, M.D., Ph.D. (contact
information provided below).
Contact Person: Anyone interested in
obtaining a roster of members or other
relevant information should write or contact
Michele A. Lloyd-Puryear, M.D., Ph.D.,
Maternal and Child Health Bureau, Health
Resources and Services Administration,
Room 18A–19, Parklawn Building, 5600
Fishers Lane, Rockville, Maryland 20857,
Telephone (301) 443–1080. Information on
the Advisory Committee is available at
https://mchb.hrsa.gov/programs/genetics/
committee.
Dated: March 11, 2005.
Tina M. Cheatham,
Director, Division of Policy Review and
Coordination.
[FR Doc. 05–5377 Filed 3–17–05; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
16:14 Mar 17, 2005
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 11, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–5371 Filed 3–17–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
BILLING CODE 4165–15–P
VerDate jul<14>2003
Name of Committee: National Cancer
Institute Special Emphasis Panel, SBIR Topic
212 Phase I & SBIR Topic 181 Phase II.
Date: April 1, 2005.
Time: 11 a.m. to 5 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: C. Michael Kerwin, PhD,
MPH, Scientific Review Administrator,
Special Review and Logistics Branch,
Division of Extramural Activities, National
Cancer Institute, National Institutes of
Health, 6116 Executive Boulevard, Room
8057, MSC 8329, Bethesda, MD 20892–8329,
301–496–7421, kerwinm@mail.nih.gov.
This notice notice is being published less
than 15 days prior to meeting due to
scheduling conflicts.
Jkt 205001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SBIR Topic
211 Phase I.
Date: April 1, 2005.
Time: 8 a.m. to 11 a.m.
Agenda: To review and evaluate contract
proposals.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
13199
Contact Person: C. Michael Kerwin, PhD,
MPH, Scientific Review Administrator,
Special Review and Logistics Branch,
Division of Extramural Activities, National
Cancer Institute, National Institutes of
Health, 6116 Executive Boulevard, Room
8057, MSC 8329, Bethesda, MD 20892–8329,
301–496–7421, kerwinm@mail.nih.gov.
This meeting is being published less than
15 days prior to meeting due to scheduling
conflicts.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 11, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–5372 Filed 3–17–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel, The Center for
Repreocutive Biological Research/
Transcription Factors in Reproduction.
Date: April 12, 2005.
Time: 3 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 5B01, Rockville,
MD 20852, (Telephone conference call.)
Contact Person: Jon M. Ranhand, PhD,
Scientist Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, NIH, 6100
E:\FR\FM\18MRN1.SGM
18MRN1
Agencies
[Federal Register Volume 70, Number 52 (Friday, March 18, 2005)]
[Notices]
[Pages 13198-13199]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-5377]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Advisory Committee on Heritable Disorders and Genetic Diseases in
Newborns and Children; Notice of Meeting
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Public Law 92-463), notice is hereby given of the
following meeting:
Name: Advisory Committee on Heritable Disorders and Genetic
Diseases in Newborns and Children (ACHDGDNC).
Dates and Times: April 21, 2005, 9 a.m. to 5 p.m., April 22,
2005, 9 a.m. to 5 p.m.
Place: Ronald Reagan Building and International Trade Center,
1300 Pennsylvania Avenue, NW., Washington, DC 20004.
Status: The meeting will be open to the public with attendance
limited to space availability.
Purpose: The Advisory Committee provides advice and
recommendations concerning the grants and projects authorized under
the Heritable Disorders Program and technical information to develop
policies and priorities for this program that will enhance the
ability of the State and local health agencies to provide for
newborn and child screening, counseling and health care services for
newborns and children having or at risk for heritable disorders.
Specifically, the Advisory Committee shall advise and guide the
Secretary regarding the most appropriate application of universal
newborn screening tests, technologies, policies,
[[Page 13199]]
guidelines and programs for effectively reducing morbidity and
mortality in newborns and children having or at risk for heritable
disorders.
Agenda: Presentations will include a discussion of the report
from the American College of Medical Genetics; reports from the
Laboratory Standards and Procedures; Education and Training; and
Follow-Up Subcommittees; a discussion on the educations process for
parents and an assessment system and guidelines for state newborn
screening follow-up.
Proposed agenda items are subject to change as priorities
indicate.
Public Comments: Time will be provided each day for public
comment. Individuals who wish to provide public comment or who plan
to attend the meeting and need special assistance, such as sign
language interpretation or other reasonable accommodations, should
notify the ACHDGDNC Executive Secretary, Michele A. Lloyd-Puryear,
M.D., Ph.D. (contact information provided below).
Contact Person: Anyone interested in obtaining a roster of
members or other relevant information should write or contact
Michele A. Lloyd-Puryear, M.D., Ph.D., Maternal and Child Health
Bureau, Health Resources and Services Administration, Room 18A-19,
Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857,
Telephone (301) 443-1080. Information on the Advisory Committee is
available at https://mchb.hrsa.gov/programs/genetics/committee.
Dated: March 11, 2005.
Tina M. Cheatham,
Director, Division of Policy Review and Coordination.
[FR Doc. 05-5377 Filed 3-17-05; 8:45 am]
BILLING CODE 4165-15-P